Ihre Browserversion ist veraltet. Wir empfehlen, Ihren Browser auf die neueste Version zu aktualisieren.


Since 2014: Villeroy & Boch

Head of Corporate Audit

Chief Audit Executive in Frankfurt listed company generating about €800 million revenue in about 120 countries around the world with production facilities in Europe, Mexico and Thailand.


2013 - 2014: SUP Societät für Unternehmensplanung, Frankfurt am Main (Germany)

Associate Partner


2011 - 2014: InterPharm Investments, London (U.K.)

Non-Executive Director


2013 – 2014 (winter semester): Louvain School of Management, Mons (Belgium)

Professor Audit & Management Control

Tenure track professor. Delivered major research projects in the field of internal audit and corporate governance. Designed curricula to guide academic development of undergraduate and graduate students in financial analysis, management accounting and performance measurement.


2001 – 2013: Actavis (Alpharma until 2005)

VP Internal Audit, VP Finance, Europe and Asia

VP Finance, CFO International

Managing Director (Geschäftsführer) of Actavis Deutschland GmbH & Co. KG.

2007-2013: Head of the Global Internal Audit department of the Actavis Group (€2 billion annual revenue - 40 countries - 10,000 employees) until 2013 when the company was sold to Watson @ $5.5 billion (then to Allergan, most lately to Teva). Established Internal Audit as highly valued business partner based on efficient and collaborative engagement with senior corporate and business unit leadership.

2006-2007: Regional CFO Europe and Asia, provided financial leadership, control and commercial support to all functional areas of non-US business units worth €1 billion in annual revenue. Conducted due diligence of over 30 mergers and acquisitions, as well as integration of 7 companies in 6 European and Asian countries. Streamlined internal transactions and reduced effective tax rates by establishing Principal Trading Company.

2001-2005: Divisional CFO of NYSE-listed Company [Formerly: ALO], served as head of the international finance team of 100 supporting International Generics and Active Pharmaceutical Ingredients business units across several multinational locations. Managed over $500 million in annual revenue.

The Global Human Pharma business including International Generics was sold to Actavis in December 2005 @ $810 million.


1997 – 2001: Schlumberger

Managing Director SEWA GmbH, Controller RMS Germany


1994 – 1997: ABB

Finance Manager


1993: apetito

Executive Assistant to the CEO